B. Artnak vs S. Markovic — prediction

The Elo differential is substantial — 1661 for Artnak against 1392 for Markovic, a 269-point gap that translates into an 82% model win probability for the favorite. In Challenger/ITF tennis this kind of gap usually reflects a real difference in consistency and shot quality, even though the market (83% implied) is pricing it almost identically.

This isn't a marginal favorite; it's a rating gap wide enough that Markovic would need a clearly superior day to close it, and nothing in the data suggests he's playing at a level that could bridge it.

Recent form reinforces the level gap rather than offsetting it. Artnak is 5-5 over his last 10 matches with a modest one-match losing streak, while Markovic has won just once in his last 10 and is mired in a seven-match losing streak.

That kind of extended skid for Markovic points to confidence and execution issues that are unlikely to reverse against a higher-rated opponent, adding a form-based layer on top of the Elo edge.

The rest picture is mixed. Artnak is playing on short rest — 5 days since his last match and two matches in the past two weeks — while Markovic has had 27 days off with no competitive matches in that span. Fresh legs can help Markovic physically, but a near month-long layoff can also mean he's short on match rhythm.

Adding to this, Artnak reached the quarterfinals at M25 Ollersbach just 5 days ago, a workload that could show up in the latter stages of a tough match. This is a real but secondary factor — not enough on its own to offset the level and form gaps, but worth weighing if the match tightens.

Being the favorite is not the same as being a value bet. Artnak's model probability (82%) sits essentially on top of the market's implied probability (83%), and the expected value here is -1.1%. That means, on average, backing the favorite at these odds is a slight loser over time, not a mispriced opportunity.

This is also a soft, less-analyzed Elo-based market rather than a fully calibrated model, so any edge — positive or negative — should be treated as an estimate, not a proven signal. The honest read: Artnak is the clear favorite on level and form, but there is no market inefficiency to exploit at the current price.